EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sprint Bioscience AB's Enterprise Value is kr320.1 Mil.
Sprint Bioscience AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was kr70.5 Mil. Therefore, Sprint Bioscience AB's EV-to-FCF for today is 4.54.
The historical rank and industry rank for Sprint Bioscience AB's EV-to-FCF or its related term are showing as below:
OSTO:SPRINT'
s EV-to-FCF Range Over the Past 10 Years
Min: -181.95 Med: -2.58 Max: 5.12
Current: 5.12
During the past 13 years, the highest EV-to-FCF of Sprint Bioscience AB was 5.12. The lowest was -181.95. And the median was -2.58.
OSTO:SPRINT's EV-to-FCF is ranked better than 65.96% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs OSTO:SPRINT: 5.12
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sprint Bioscience AB (OSTO:SPRINT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sprint Bioscience AB's PE Ratio (TTM) for today is calculated as:
Sprint Bioscience AB's share price for today is kr4.06.
Sprint Bioscience AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.780.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sprint Bioscience AB EV-to-FCF Related Terms
Sprint Bioscience AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Sprint Bioscience AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPRINT vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Sprint Bioscience AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sprint Bioscience AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sprint Bioscience AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sprint Bioscience AB's EV-to-FCF falls into.
Sprint Bioscience AB's current Enterprise Value is kr320.1 Mil.
Sprint Bioscience AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr70.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sprint Bioscience AB (OSTO:SPRINT) has a EV-to-FCF of 4.54 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sprint Bioscience AB and its competitors. According to the industry distribution chart, Sprint Bioscience AB ranks #113 out of 332 companies in the Biotechnology industry, placing it in the top 34%.
Is Sprint Bioscience AB's EV-to-FCF too high?
Sprint Bioscience AB's current EV-to-FCF is 4.54. The Biotechnology industry median EV-to-FCF is 16.26. Sprint Bioscience AB's value of 4.54 is 72.1% below this industry median. Based on the distribution chart, Sprint Bioscience AB ranks #113 out of 332 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Sprint Bioscience AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sprint Bioscience AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sprint Bioscience AB ranks #113 out of 332 companies for EV-to-FCF. This puts Sprint Bioscience AB in the upper half of its industry. The industry median EV-to-FCF is 16.26. Sprint Bioscience AB's value of 4.54 is 72.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sprint Bioscience AB's current EV-to-FCF of 4.54 is 72.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Sprint Bioscience AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sprint Bioscience AB's current EV-to-FCF is 4.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sprint Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Sprint Bioscience AB (OSTO:SPRINT) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.18, compared to a current price of kr4.06 — trading 86.2% above its estimated fair value. The current EV-to-FCF is 4.54 and 72.1% below the Biotechnology industry median of 16.26. Sprint Bioscience AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Sprint Bioscience AB (OSTO:SPRINT), the current EV-to-FCF is 4.54 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sprint Bioscience AB (OSTO:SPRINT) Overvalued in 2026?
Based on GuruFocus' analysis, Sprint Bioscience AB stock appears to be overvalued.
The current stock price of kr4.06 is trading 86.2% above its estimated GF Value™ of kr2.18.
GuruFocus considers Sprint Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPRINT:
EV-to-FCF: 4.54
GF Value™: kr2.18 vs. price of kr4.06 (86.2% above fair value)
Industry Position: 72.1% below the Biotechnology median (#113 of 332)
No single metric tells the full story. See the OSTO:SPRINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
32GF Score
Get the complete analysis for OSTO:SPRINT
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPRINT has been successfully added to your 
